ÈËÉú¾ÍÊDz©

EN
ÈËÉú¾ÍÊDz©_Ê×Ò³Èë¿Ú
¸ÄÁ¼CAR-Tϸ°ûÁÆ·¨£¡×îÐÂScience×Ó¿¯Ñо¿£ºTOP CAR-Tϸ°ûÁÆ·¨ÔÚʵÌåÁöÖÎÁÆÁìÓò»ñµÃÖØ´óÍ»ÆÆ
2024/07/12

ÔÚÒ»ÏîеÄÑо¿ÖÐ £¬£¬À´×Ô°¢¶û²®ÌØ-°®Òò˹̹ҽѧԺµÄÑо¿Ö°Ô±È¡µÃÁËÖØ´óÏ£Íû £¬£¬ËûÃÇ·¢Ã÷ÁËÒ»ÖÖ¸ÄÁ¼µÄCAR-Tϸ°ûÁÆ·¨ £¬£¬¸ÃÁÆ·¨Õë¶ÔʵÌåÁöÕ¹ÏÖ³öÁËØ¨¹ÅδÓеÄÁÆÐ§ £¬£¬ÕâһЧ¹û»ò½«ÖØËܰ©Ö¢ÖÎÁÆÃûÌᣡ£¡£¡£¡£Ïà¹ØÑо¿Ð§¹û½üÆÚ½ÒÏþÔÚScience AdvancesÆÚ¿¯ÉÏ £¬£¬ÂÛÎÄÎÊÌâΪ¡°TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors¡±¡£¡£¡£¡£¡£

Ñо¿Í¨Ñ¶×÷ÕßXingxing Zang²©Ê¿ÌåÏÖ£º¡°CAR-Tϸ°ûÁÆ·¨ÔÚѪ°©ÖÎÁÆÁìÓòÒÑÈ¡µÃ¸ïÃüÐԳɼ¨ £¬£¬µ«ÔÚʵÌåÁöÑÛǰȴһÔÙÊÜ´ì¡£¡£¡£¡£¡£ÎÒÃǾªÏ²µØ·¢Ã÷ £¬£¬Í¨¹ýÓÅ»¯±ê×¼CAR-Tϸ°ûÁÆ·¨ £¬£¬Æä¶ÔʵÌåÁö £¬£¬ÓÈÆäÊÇÒÈÏÙ°©ºÍ½ºÖÊĸϸ°ûÁöÕâÀàÄÑÖÎÐÔ°©Ö¢µÄÖÎÁÆÐ§¹û»ñµÃÁËÏÔÖøÌáÉý¡£¡£¡£¡£¡£¡±

¿ª·¢¸öÐÔ»¯°©Ö¢É±ÊÖ

Zang²©Ê¿ºÍËûµÄͬÊÂÃÇ¿ª·¢³öÎåÖÖCAR-Tϸ°ûÁÆ·¨ £¬£¬²¢ÔÚÒÆÖ²ÁËÈËÀàʵÌåÁöµÄСÊóÄ£×ÓÉϾÙÐÐÁËʵÑé¡£¡£¡£¡£¡£ÆäÖÐ £¬£¬Ò»ÖÖÁÆ·¨ÒòÈÚºÏÁËÁ½ÏîÐÂÓ±ÔªËØ¶øÍÑÓ±¶ø³ö £¬£¬Ëü²»µ«Çå¾²ÓÐÓõØËõ¼õÁ˽ºÖÊĸϸ°ûÁöºÍÒÈÏÙÖ×Áö £¬£¬Í¬Ê±Ò²¶Ô·Î°©Ö×Áö±¬·¢ÁËÏÔÖøµÄÒÖÖÆÐ§¹û¡£¡£¡£¡£¡£

CAR-Tϸ°ûÁÆ·¨ £¬£¬È«³ÆÇ¶ºÏ¿¹Ô­ÊÜÌåTϸ°ûÁÆ·¨ £¬£¬±»ÓþΪ»ùÒò¹¤³ÌµÄ½Ü×÷ £¬£¬Äܹ»½«ÃâÒßϵͳÖеÄTϸ°ûת»¯Îª¾«×¼¹¥»÷°©Ï¸°ûµÄ¡°»îÌåµ¼µ¯¡±¡£¡£¡£¡£¡£¸ÃÁÆ·¨Éæ¼°´Ó»¼ÕßÌåÄÚÌáÈ¡Tϸ°û £¬£¬²¢Í¨¹ý»ùÒò¹¤³ÌÊÖÒÕÖ²Èë±àÂëCARµÄ»ùÒò¡£¡£¡£¡£¡£¾­ÓÉˢеÄCAR-Tϸ°û¿ÉÔÚÌåÍâ´ó×ÚÀ©Ôö £¬£¬Ëæºó»ØÊäÖÁ»¼ÕßÌåÄÚ £¬£¬ÆäÍâò±í´ïµÄºÏ³ÉCARÊÜÌåÄܹ»Ê¶±ð²¢Ëø¶¨°©Ï¸°ûÉϵÄÌØ¶¨¿¹Ô­ £¬£¬´¥·¢Tϸ°ûµÄ¹¥»÷»úÖÆ¡£¡£¡£¡£¡£

ÎåÖÖCAR-Tϸ°û¶Ô¿¹ÈýÖÖ°©Ö¢

Zang²©Ê¿ÍŶӵÄÎåÖÖCAR-Tϸ°ûÁÆ·¨¾ù½ÓÄÉÁËͳһÖÖÐÂÐ͵İÐÏòÂѰסª¡ªÒ»ÖÖÄÜÓëB7-H3Á¬ÏµµÄµ¥¿Ë¡¿¹Ìå £¬£¬B7-H3ÊÇÒ»Ö֯ձ鱣´æÓÚ´ó¶¼ÊµÌåÁö¼°ÆäѪ¹ÜÍâòµÄ¿¹Ô­¡£¡£¡£¡£¡£ÔÚ´ËǰµÄÑо¿ÖÐ £¬£¬Zang²©Ê¿ÒÑÕ¹ÏÖB7-H3ÔõÑù×ÌÈÅTϸ°û¹¦Ð§ £¬£¬Ð­ÖúÖ×ÁöÌÓ×ßÃâÒßϵͳµÄ×·²¶¡£¡£¡£¡£¡£ÎªÁËսʤÕâÒ»Õϰ­ £¬£¬Zang²©Ê¿Ö¸³ö£º¡°ÎÒÃÇÏ£ÍûÉè¼ÆµÄCAR²»µ«ÄÜÖ¸µ¼Tϸ°û¶¨Î»ÊµÌåÁö £¬£¬»¹ÄÜͨ¹ýÌØÒìÐÔÁ¬ÏµB7-H3 £¬£¬×èÖ¹ÆäÏ÷ÈõTϸ°û¹¥»÷ºÍɨ³ý°©Ï¸°û¼°ÆäѪ¹ÜµÄÄÜÁ¦¡£¡£¡£¡£¡£¡±

È»¶ø £¬£¬½ö¿¿Á¬ÏµÖ×Áöϸ°ûÉÐȱ·¦ÒÔÈ·±£°©Ï¸°ûµÄéæÃü¡£¡£¡£¡£¡£ÎªÁ˼¤»îTϸ°û £¬£¬CAR»¹Ðè°üÀ¨Ò»ÖÖ¹²´Ì¼¤ÂѰס£¡£¡£¡£¡£ÔÚZang²©Ê¿ÊµÑéÊÒÑз¢µÄÎåÖÖCAR-Tϸ°ûÁÆ·¨ÖÐ £¬£¬ËÄÖÖ½ÓÄÉÁË´«×ܹ²´Ì¼¤ÂÑ°× £¬£¬¶øµÚÎåÖÖÔòÒýÈëÁËÒ»ÖÖØ¨¹ÅδÓеÄÂѰסª¡ªTMIGD2¡£¡£¡£¡£¡£

2015Äê £¬£¬Zang²©Ê¿·¢Ã÷Tϸ°ûÓµÓÐÒ»ÖÖ³ÆÖ®TMIGD2µÄÊÜÌå £¬£¬ÕâÖÖÊÜÌåÔÚÊܵ½´Ì¼¤Ê±Äܼ¤»îTϸ°û£¨Clinical Cancer Research, 2025, doi:10.1158/1078-0432.CCR-14-1495£©¡£¡£¡£¡£¡£ËûØÊºóÒâʶµ½ £¬£¬½«TMIGD2ÕûÈëµ½CAR-Tϸ°û¿ÉÄÜʹËüÃÇսʤʵÌåÁö´øÀ´µÄÌôÕ½¡£¡£¡£¡£¡£

ÈËÉú¾ÍÊDz©_Ê×Ò³Èë¿Ú 

ͼƬÀ´×ÔScience Advances, 2024, doi:10.1126/sciadv.adk1857

¡°ÊµÌåÁöÄÚ²¿µÍÑõÌõ¼þÓëÃâÒß¼ì²éµãµÄ±£´æ £¬£¬ÐγÉÁËÒ»¸ö¶ÔTϸ°û¼«Æäµ¹Ô˵Ä΢ÇéÐÎ £¬£¬ÏÞÖÆÁËËüÃǵÄÉøÍ¸ÄÜÁ¦ºÍÃâÒß¹¥»÷Á¦¡£¡£¡£¡£¡£TMIGD2×÷Ϊ¹²´Ì¼¤ÂÑ°× £¬£¬ËƺõÄܹ»ÎªCAR-Tϸ°û×¢Èë×ã¹»µÄ¶¯Á¦ £¬£¬Ê¹Æä´©Í¸ÊµÌåÁöµÄ÷缯½áµÞ×éÖ¯ £¬£¬µÖ´ï°©Ï¸°û²¢ºã¾ÃפÁô¡£¡£¡£¡£¡£¡±Zang²©Ê¿Ú¹Ê͵À¡£¡£¡£¡£¡£

TOP CAR

ʵÑéЧ¹ûÏÔʾ £¬£¬Ð¯´øÒÈÏÙ°©¡¢·Î°©ºÍ½ºÖÊĸϸ°ûÁöµÄСÊóÔÚ½ÓÊÜÁËÐÂÐÍCAR-Tϸ°ûÁÆ·¨ºó £¬£¬Õ¹ÏÖ³öÁîÈ˹ÄÎèµÄÁÆÐ§¡£¡£¡£¡£¡£ÆäÖÐ £¬£¬×îÒýÈËעĿµÄÁÆ·¨Á¬ÏµÁËÐÂÐÍ¿¹ÌåÓëTMIGD2ÂÑ°× £¬£¬±»ÃüÃûΪTMIGD2ÓÅ»¯Ð§Á¦/³¤ÆÚÐÔ£¨Optimized Potent/Persistent, TOP£©CAR¡£¡£¡£¡£¡£

ʹÓÃTOP CARµÄCAR-Tϸ°ûÁÆ·¨ÔÚÒÈÏÙ¡¢·ÎºÍ½ºÖÊĸϸ°ûÁöСÊóÄ£×ÓÖÐÌåÏÖ׿Խ £¬£¬ÏÔÖøÌá¸ßÁËСÊóµÄ´æ»îÂÊ¡£¡£¡£¡£¡£ÀýÈç £¬£¬ÔÚ½ºÖÊĸϸ°ûÁöСÊóÖÐ £¬£¬TOP CAR Tϸ°ûÁÆ·¨Ê¹7Ö»ÖеÄ6Ö»´æ»îÏÂÀ´ £¬£¬¶øÆäËûCAR-TÁÆ·¨½öÄÜÕü¾È3Ö»ÖеÄ1Ö»¡£¡£¡£¡£¡£±ðµÄ £¬£¬TOP CAR Tϸ°ûÁÆ·¨ÔÚÓÐÓÃÐÔºÍÇå¾²ÐÔÖ¸±êÉϾùÕ¹ÏÖ³öÓÅÊÆ¡£¡£¡£¡£¡£

Õ¹ÍûδÀ´ £¬£¬Zang²©Ê¿ÍýÏë½øÒ»²½ÍêÉÆTOP CARÊÖÒÕ £¬£¬¹¹½¨Ò»¸ö¡°Ïֳɡ±Æ½Ì¨ £¬£¬¸Ãƽ̨²»µ«ÄܰÐÏòB7-H3 £¬£¬»¹¿Éͬʱʶ±ð¶àÖÖÖ×Áö¿¹Ô­ £¬£¬ÊÊÓÃÓÚÖÖÖÖʵÌåÁöµÄÖÎÁÆ¡£¡£¡£¡£¡£

°¢¶û²®ÌØ-°®Òò˹̹ҽѧԺÒѶÔZang²©Ê¿µÄ¿ÆÑÐЧ¹û½ÓÄÉÁË֪ʶ²úȨ±£»£»£»£»£»£»¤²½·¥ £¬£¬²¢ÕýÆð¾¢×·ÇóÉÌÒµÏàÖúͬ°é £¬£¬Ö¼ÔÚ½«ÕâÖÖË¢ÐÂÐÔµÄTOP CAR Tϸ°ûÁÆ·¨¾¡¿ìÍÆ½øÖÁÁÙ´²ÊÔÑé½×¶Î £¬£¬ÎªÄÔ°©¡¢¸Î°©¡¢ÒÈÏÙ°©¡¢Âѳ²°©¡¢Ç°ÏßÏÙ°©¡¢·Î°©¡¢°òë×°©ºÍ½á³¦°©µÈ¶àÖÖ°©Ö¢»¼Õß´øÀ´¸£Òô¡£¡£¡£¡£¡£

·µ»Ø
¡¾ÍøÕ¾µØÍ¼¡¿